Albany Molecular Research Inc (AMRI): Steven R Hagen , SVP Manufacturing & Pharmaceut of Albany Molecular Research Inc sold 2,361 shares on May 13, 2016. The Insider selling transaction was reported by the company on May 16, 2016 to the Securities and Exchange Commission. The shares were sold at $12.77 per share for a total value of $30,149.97 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 16, 2016, William S Marth (CEO) purchased 12,500 shares at $12.86 per share price.On Nov 10, 2015, Ambra Constance M D (10% owner) sold 50,000 shares at $19.60 per share price.Also, On Nov 10, 2015, Ambra Thomas E D (director other) sold 50,000 shares at $19.60 per share price.On Aug 17, 2015, Steven R Hagen (SVP Manufacturing & Pharmaceut) sold 1,000 shares at $20.45 per share price.
Shares of Albany Molecular Research (AMRI) ended Friday, May 13, 2016 session in red amid volatile trading. The shares closed down -0.21 points or -1.64% at $12.58 with 2,82,264 shares getting traded. Post opening the session at $12.78, the shares hit an intraday low of $12.51 and an intraday high of $12.957 and the price vacillated in this range throughout the day. The company has a market cap of $449 M and the number of outstanding shares has been calculated to be 3,57,03,100 shares. The 52-week high of Albany Molecular Research is $22.48 and the 52-week low is $12.45.
Albany Molecular Research Inc. is a global contract research and manufacturing organization providing drug discovery development and manufacturing services. The Company operates in three business segments: Discovery and Development Services (DDS) API and Drug Product. The Company offers a portfolio of services from target identification tools to investigational new drug (IND) enabling activities. The Company’s manufacturing facilities are situated in various locations in the United States Europe and Asia. The Company provides state-of-the-art facilities and solutions to deliver integrated pharmaceutical drug development programs and services including process research and development pre-formulation and formulation development good laboratory practices (GLP) bioanalytical and separation sciences.